Lung cancer (Q81086287)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Giuseppe Giaccone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Egbert Smit

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json

Cancer chemotherapy and biological response modifiers

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

413-442

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json

Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958).

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Sequential chemoradiotherapy versus radiotherapy in the management of locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung--a Kansas Cancer Institute and Thompson Cancer Survival Center Study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of paclitaxel (Genaxol) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Combined Therapy with Topotecan and Gemcitabine in Patients with Inoperable or Metastatic Non-small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II study of vinorelbine, mitomycin C and cisplatin chemotherapy for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of Taxol combined With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience from a Single Institution

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Randomized clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923).

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI)

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Combination Chemotherapy with Gemcitabine and Vinorelbine in the Treatment of Patients with Relapsed or Refractory Small Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I Study of Weekly Alternating Therapy with Irinotecan/Cisplatin and Etoposide/Cisplatin for Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992)

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922019-1

7 January 2021

10.1016/S0921-4410(04)22019-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110623%20AND%20SRC:MED&resulttype=core&format=json